# A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

> **NCT05521191** · PHASE1 · COMPLETED · sponsor: **Regulus Therapeutics Inc.** · enrollment: 68 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease
- ADPKD
- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** RGLS8429
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05521191
- **Lead sponsor:** Regulus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-06
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-03-27
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05521191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05521191, "A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05521191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*